ENABLE-2 programmes
ENABLE-2 is currently supporting eight promising programmes in the pursuit of new antibiotics. These have their scientific basis at: Technische Universität Berlin • Justus Liebig University Giessen • The Ineos Oxford Institute at the University of Oxford • Global Antibiotic R&D Partnership • University of Lille & Institut Pasteur de Lille • University of Ljubljana.
Programme Albisolv
A new type of broad spectrum gyrase inhibitor active against fluoroquinolone-resistant bacteria.
Resident at
Contact
Roderich Süssmuth, Professor, Principal Investigator
Technische Universität Berlin
Roderich.Suessmuth@tu-berlin.de
BamA Inhibitors Programme
Novel antibiotics that hit a new target against Gram-negative bacteria.
Resident at
Contact
Till F. Schäberle, PhD, Principal Investigator
Justus Liebig University Giessen
Till.F.Schaeberle@agrar.uni-giessen.de
Boron-Based SBL/MBL Inhibitors Programme
Novel boron-based inhibitors targeting serine- and metallo-beta-lactamases that restore activity of beta-lactams against MDR Gram-negative Enterobacterales.
Resident at
Contact
Alen Krajnc, PhD, Principal Investigator
University of Ljubljana, Faculty of Pharmacy
Alen.Krajnc@ffa.uni-lj.si
Broad-spectrum MBL inhibitors Programme
A new class of broad spectrum metallo-b-lactamase inhibitors that restore activity of carbapenems in MDR Gram-negative Enterobacterales
Resident at
Contact
Alistair Farley, Dr, Scientific Lead
Ineos Oxford Institute at the University of Oxford
Alistair.farley@chem.ox.ac.uk
Christopher Schofield
Professor of Chemistry, University of Oxford
Director of Chemistry, Ineos Oxford Institute at the University of Oxford
Christopher.schofield@chem.ox.ac.uk
Efflux Pump Inhibitors Programme
Novel AcrB efflux pump inhibitors to restore antibiotic activity against MDR Enterobacterales.
Resident at
Contact
Marion Flipo, Dr.
University of Lille
marion.flipo@univ-lille.fr
Ruben C. Hartkoorn, Dr.
Institut Pasteur de Lille
ruben.hartkoorn@inserm.fr
LolCDE inhibitors Programme
A novel antibiotic class that targets the LolCDE lipoprotein transporter in multidrug-resistant Enterobacterales.
Resident at
Contact
Alan Hennessy, Head of Discovery
GARDP
Ahennessy@gardp.org
Tetracycline Destructase Inhibitors Programme
Novel Tet(X) inhibitors that restore tetracycline activity against drug-resistant Gram-negative pathogens.
Resident at
Contact
Christopher Schofield
Professor of Chemistry, University of Oxford
Director of Chemistry, Ineos Oxford Institute at the University of Oxford
Christopher.schofield@chem.ox.ac.uk
Tricyclic Transpeptidase Inhibitors Programme
A novel class of beta-lactams active against multidrug-resistant Gram-negative bacteria.
Resident at
Contact
Christopher Schofield
Professor of Chemistry, University of Oxford
Director of Chemistry, Ineos Oxford Institute at the University of Oxford
Christopher.schofield@chem.ox.ac.uk
Learn more
Contact ENABLE-2
Marie Olliver, PhD, Alliance Manager
Uppsala University
Marie.Olliver@ilk.uu.se
ENABLE-2 funders
ENABLE-2 is supported by the Swedish Research Council and the National Research Programme on Antibiotic Resistance.
